Life Science Entrepreneurs, Cardiologists, & Circulatory Support Experts
Procyrion is dedicated to improving the quality of life of millions of heart failure patients through the development of safe and innovative circulatory assist devices. Procyrion is currently engaged in the development of the Aortix™ heart pump, designed to be the first non-surgical, minimally invasive, catheter deployed heart pump for long-term use. Aortix may improve the quality of life of millions of NYHA Stage III and early Stage IV heart failure patients.
Experienced start-up entrepreneur with a focus on medical devices, diagnostics and healthcare services. Managing Director of AlphaDev LLC; Vice President of BCM Technologies; McKinsey & Co. (Member of Pharmaceutical and Medical Products Practice); Ph.D. from Brown University’s Artificial Organs, Biomaterials, and Cellular Technology program.
Practicing cardiologist and leader in the field of heart failure. Medical Director, Mechanical Support Devices in Heart Failure, Texas Heart Institute; Advisory Board, Boston Scientific (LATITUDE HF monitoring system); Author on two NEJM articles that led to the FDA approval of the Heartmate II™ LVAD.
Experienced venture-backed founder of three start-ups; McKinsey & Co. consultant with CV OR and cath-lab focused engagements; Ph.D. from Oxford University in Sensors, Sensor Fusion, Control Systems, and Artificial Vision.
Beth brings to Procyrion more than 20 years of experience as a global regulatory affairs leader, having played a key role in the approval of neuromodulation and cardiac devices. She has been integral in successful US and international registrations for clinical trials and commercial product approvals.
Medical entrepreneur with device development experience. MD: Baylor College of Medicine; B.S. Biomedical Engineering: University of Southern California; Howard Hughes Medical Research Fellow; Percutaneous Glucose Sensor Research and Development, Alfred Mann Institute for Biomedical Engineering, Los Angeles, CA.
Katherine is an experienced Quality Assurance professional, highly knowledgeable and skilled in Quality Engineering and in developing, implementing and maintaining Quality Management Systems compliant with 21 CFR 820, ISO 13485 and international regulations for successful 510k / CE Mark device registration and PMA approval.
Accomplished bioengineer and medical device entrepreneur with extensive experience in structural heart research; experience in world-class labs in both the US and Europe, developing enabling technologies for the treatment of valve disease; BS with highest honors from the Georgia Institute of Technology; PhD in Bioengineering from Rice University.
An accomplished medical device designer with 24 years of experience in successfully commercializing new and novel products. Ronnie has experience with implant delivery systems, conceiving and designing new devices, developing production equipment, and contributing to FDA regulatory submissions.
Scientist in the field of cardiovascular tissue engineering with experience in circulatory support devices and computer-aided design; Ph.D. Bioengineering, Rice University’s Pediatric Cardiovascular Bioengineering Lab at Texas Children’s Hospital; B.S. Biomedical Engineering, University of Texas at Austin.
A medical device engineer with over 25 years of experience in the medical device industry. Christian has worked for medical device startup companies successfully developing oral cancer screening devices and blood warmers for emergency first responders.
A serial entrepreneur with extensive experience in the securities industry. Founded an investment advisory company, developed a family of alternative indexing products, and provided option education services. Previously Director of OTC Trading at Mercury Trading, a member of the Chicago Board Options Exchange, and a member of the CBOE's Product Development Committee.
Biomedical engineer with experience in surgical techniques and methods in the pre-clinical setting, primarily with a focus in circulatory support devices and cardiovascular interventional applications. MS in Biomedical Engineering from the joint program at the University of Texas at Arlington and the University of Texas Southwestern. BS in Biology from the University of Texas at Arlington.
Mr. Burbach, an accomplished medical device executive, joined Procyrion’s Board as an Independent Director in February 2016. From January 2006 to September 2014, Mr. Burbach served as president, chief executive officer, and director of Thoratec Corporation (NASDAQ: THOR).
Leo Linbeck III is the Chairman and Founder of Fannin Innovation Studio. Leo is also President and CEO of the Aquinas Companies, LLC, which sponsored Fannin for five years to validate its model before bringing in outside investors for scale-up. Leo graduated from the University of Notre Dame with both Civil Engineering and Liberal Arts degrees and received a Master’s in Structural Engineering from the University of Texas. He earned his MBA from the Stanford University Graduate School of Business.
Carter Meyer is the Chief Executive Officer of Scientific Health Development (SHD) since its formation in February 2006, and is a General Partner of SHD II and SHD III. Prior to joining SHD, he was an attorney in private practice for over 12 years, most recently with the Dallas office of the Vinson & Elkins L.L.P.
Marc Chaput is a Partner at Gravitas Healthcare, a strategic advisory firm focused on emerging growth medical device companies. Prior to Gravitas, he was a Director in Cowen & Co.'s health care investment banking group, and prior to that he worked in the health care group at Deutsche Bank. He is also on the Advisory Committee of Sweetwater Capital Partners and represents the State of Texas on the Procyrion board.
Professor, Department of Internal Medicine, University of Michigan; Medical Director, Heart Failure Program; Specialty: Cardiology, Cardiovascular Medicine; Clinical Interests: Heart failure and heart transplantation;
Dr. Birks began her work in Ventricular Assist Devices in 1996 when she accepted a research position with the VAD program at the Royal Brompton and Harefield Hospital in London.
Manesh R. Patel, MD, Chief of the Division of Cardiology for Duke's Department of Medicine, is an associate professor of medicine, a member of the Duke Clinical Research Institute, and director of Interventional Cardiology and Cardiac Catheterization Labs across the Duke University Health System.
Senior Vice Chair in the Duke Department of Medicine. In addition, he has been named Associate Chief Medical Officer of the Private Diagnostic Clinic (PDC), where he will oversee the PDC clinical growth over the next five years.
Dr. Hani N. Sabbah is a tenured Professor of Medicine at Wayne State University in Detroit and the Director of Cardiovascular Research at the Henry Ford Health System in Detroit.